Search

Your search keyword '"Hagar, Ward"' showing total 44 results
Start Over Author "Hagar, Ward"
44 results on '"Hagar, Ward"'

1. A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease

Author

Hankins, Jane S, Brambilla, Donald, Potter, Michael B, Kutlar, Abdullah, Gibson, Robert, King, Allison A, Baumann, Ana A, Melvin, Cathy, Gordeuk, Victor R, Hsu, Lewis L, Nwosu, Chinonyelum, Porter, Jerlym S, Alberts, Nicole M, Badawy, Sherif M, Simon, Jena, Glassberg, Jeffrey A, Lottenberg, Richard, DiMartino, Lisa, Jacobs, Sara, Fernandez, Maria E, Bosworth, Hayden B, Klesges, Lisa M, Shah, Nirmish, Hodges, Jason, Carroll, Yvonne, Klesges, Lisa, Khan, Hamda, Smeltzer, Matthew, Gurney, James, Porter, Jerlym, Alberts, Nicole, French, Reginald, Badawy, Sherif, DeBaun, Michael, Kang, Guolian, Estepp, Jeremie, Wang, Winfred, Owens, Curtis, Debon, Margaret, Osarogiagbon, Ray, Nelson, Marquita, Treadwell, Marsha, Vichinsky, Elliott, Wun, Ted, Potter, Michael, Hessler, Danielle, Hagar, Ward, Marsh, Anne, Neumayr, Lynne, Kanter, Julie, Phillips, Shannon, Adams, Robert, Mueller, Martina, Abrams, Tina, Davia, Nathalia, Tanabe, Paula, Bosworth, Hayden, Jackson, George, Johnson, Fred, Richesson, Rachel, Prvu-Bettger, Janet, King, Allison, Baumann, Ana, Calhoun, Cecilia, Snyder, Angie, Fernandez, Maria, Richardson, Lynne D, Glassberg, Jeffrey, Genes, Nicholas G, Loo, George T, Shapiro, Jason S, Souffront, Kimberly, Clesca, Cindy, Linton, Elizabeth, Ryan, Gery, Kroner, Barbara L, Hendershot, Tabitha, Battestilli, Whitney, Cox, Lisa, Preiss, Liliana, Pugh, Norma, Li, Sophie, VonLehmden, Annie, Smith, Sharon M, Tonkins, William P, Peters-Lawrence, Marlene, Boyce, Cheryl, Barfield, Whitney, and Thompson, Alexis

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Health Services, Clinical Trials and Supportive Activities, Chronic Pain, Pain Research, Hematology, Sickle Cell Disease, Clinical Research, Rare Diseases, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Adult, Female, Humans, Male, Anemia, Sickle Cell, Hydroxyurea, Medication Adherence, Pain, Telemedicine, Cardiovascular medicine and haematology
Abstract

Hydroxyurea reduces sickle cell disease (SCD) complications, but medication adherence is low. We tested 2 mobile health (mHealth) interventions targeting determinants of low adherence among patients (InCharge Health) and low prescribing among providers (HU Toolbox) in a multi-center, non-randomized trial of individuals with SCD ages 15-45. We compared the percentage of days covered (PDC), labs, healthcare utilization, and self-reported pain over 24 weeks of intervention and 12 weeks post-study with a 24-week preintervention interval. We enrolled 293 patients (51% male; median age 27.5 years, 86.8% HbSS/HbSβ0-thalassemia). The mean change in PDC among 235 evaluable subjects increased (39.7% to 56.0%; P < 0.001) and sustained (39.7% to 51.4%, P < 0.001). Mean HbF increased (10.95% to 12.78%; P = 0.03). Self-reported pain frequency reduced (3.54 to 3.35 events/year; P = 0.041). InCharge Health was used ≥1 day by 199 of 235 participants (84.7% implementation; median usage: 17% study days; IQR: 4.8-45.8%). For individuals with ≥1 baseline admission for pain, admissions per 24 weeks declined from baseline through 24 weeks (1.97 to 1.48 events/patient, P = 0.0045) and weeks 25-36 (1.25 events/patient, P = 0.0015). PDC increased with app use (P < 0.001), with the greatest effect in those with private insurance (P = 0.0078), older subjects (P = 0.033), and those with lower pain interference (P = 0.0012). Of the 89 providers (49 hematologists, 36 advanced care providers, 4 unreported), only 11.2% used HU Toolbox ≥1/month on average. This use did not affect change in PDC. Tailoring mHealth solutions to address barriers to hydroxyurea adherence can potentially improve adherence and provide clinical benefits. A definitive randomized study is warranted. This trial was registered at www.clinicaltrials.gov as #NCT04080167.

Published
2023

2. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial

Author

Gladwin, Mark T, Gordeuk, Victor R, Desai, Payal C, Minniti, Caterina, Novelli, Enrico M, Morris, Claudia R, Ataga, Kenneth I, De Castro, Laura, Curtis, Susanna A, El Rassi, Fuad, Ford, Hubert James, Harrington, Thomas, Klings, Elizabeth S, Lanzkron, Sophie, Liles, Darla, Little, Jane, Nero, Alecia, Smith, Wally, Taylor, James G, VI, Baptiste, Ayanna, Hagar, Ward, Kanter, Julie, Kinzie, Amy, Martin, Temeia, Rafique, Amina, Telen, Marilyn J, Lalama, Christina M, Kato, Gregory J, and Abebe, Kaleab Z

Published
2024
Full Text
View/download PDF

3. Impact of an individualized pain plan to treat sickle cell disease vaso-occlusive episodes in the emergency department

Author

Hodges, Jason, Carroll, Yvonne, Smeltzer, Matthew, Nwosu, Chinonyelum, Gurney, James, Potter, Jerlym, Badawy, Sherif, Estepp, Jeremie, Treadwell, Marsha, Vichinsky, Elliott, Wun, Ted, Potter, Michael, Hessler, Danielle, Hagar, Ward, Marsh, Anne, Neumayr, Lynne, Melvin, Cathy, Kanter, Julie, Phillips, Shannon, Adams, Robert, Mueller, Martina, Davila, Caroline, Nirmish Shah, Sarah Bourne., Tanabe, Paula, Bosworth, Hayden, Jackson, George, Richesson, Rachel, Prvu-Bettger, Janet, Masese, Rita, DeMartino, Terri, Kutlar, Abdullah, Gibson, Robert, Snyder, Angela, Fernandez, Maria, Lyon, Matthew, Lottenberg, Richard, Lawrence, Raymona, Gollan, Sierra, Bowman, Latanya, Richardson, Lynne, Glassberg, Jeffrey, Simon, Jena, Loo, George T., Clesca, Cindy, Linton, Elizabeth, Ryan, Gery, Gordeuk, Victor, Hirschtick, Jana, Hsu, Lewis, Krishnan, Jerry, Wandersman, Abe, Colla, Joe, Erwin, Kim, Lamont, Andrea, Norell, Sarah, Saving, Kay, Nocek, Judith, King, Allison, Baumann, Ana, Calhoun, CeCe, Luo, Lingzi, James, Aimee, Abel, Regina, Varughese, Taniya, Kroner, Barbara, Rojas-Smith, Lucia, Hendershot, Tabitha, DiMartino, Lisa, Jacobs, Sara, Battestilli, Whitney, Brambilla, Don, Cox, Lisa, Preiss, Liliana, Pugh, Norma, Telfair, Joseph, Hassell, Kathryn, Thompson, Alexis, Tompkins, William, Smith, Sharon, Luksenberg, Harvey, Peters-Lawrence, Marlene, Boyce, Cheryl, Barfield, Whitney, Werner, Ellen, Siewny, Lauren, Melvin, Cathy L., Carpenter, Christopher R., Hankins, Jane S., Colla, Joseph S., Davila, Natalia, Masese, Rita V., McCuskee, Sarah, and Gollan, S. Siera

Published
2024
Full Text
View/download PDF

5. Influence of sickle cell disease on susceptibility to HIV infection

Author

Kelly, Shannon, Jacobs, Evan S, Stone, Mars, Keating, Sheila M, Lee, Tzong-Hae, Chafets, Daniel, Heitman, John, Dimapasoc, Melanie, Operskalski, Eva, Hagar, Ward, Vichinsky, Elliott, Busch, Michael P, Norris, Philip J, and Custer, Brian

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Infectious Diseases, Clinical Research, Sickle Cell Disease, Rare Diseases, HIV/AIDS, Hematology, 2.1 Biological and endogenous factors, Aetiology, Infection, Good Health and Well Being, Adolescent, Adult, Anemia, Sickle Cell, Blood Safety, Blood Transfusion, CD4-Positive T-Lymphocytes, Cell Line, Cytokines, Disease Susceptibility, Female, HIV, HIV Infections, Humans, Male, Middle Aged, Prospective Studies, Protective Factors, Retrospective Studies, Risk Factors, Transfusion Reaction, Young Adult, Recipient Epidemiology and Donor Evaluation Study, General Science & Technology
Abstract

People with sickle cell disease (SCD) are reported to have low rates of HIV infection, slower progression to AIDS and lower HIV-associated mortality compared to the general population. Mechanisms of potential resistance to HIV in SCD are incompletely understood. We retrospectively reviewed the Transfusion Safety Study to compare HIV status between people with SCD and other congenital anemias who were routinely exposed to blood products during the high-risk period before HIV screening implementation. Non-SCD congenital anemia diagnosis was associated with a higher risk of HIV acquisition compared to SCD (OR 13.1 95%CI 1.6-108.9). In addition, we prospectively enrolled 30 SCD cases and 30 non-SCD controls to investigate potential mechanisms of resistance to HIV in SCD. CCR5 and CCR7 expression was lower and CD4 expression was higher on CD4+ T cells from SCD cases compared to controls. Surface expression of CD4+ T cell CXCR4, CD38 and HLA-DR did not differ between the groups. SCD CD4+ T cells were not less susceptible to HIV infection than controls. Levels of multiple cytokines were elevated in the SCD plasma, but SCD plasma compared to control plasma did not inhibit HIV infection of target cells. In conclusion, our epidemiological data support people with SCD being resistant to HIV infection. Potential mechanisms include lower CD4+ T cell expression of CCR5 and CCR7, balanced by increased CD4 expression and cytokine levels, which did not result in in vitro resistance to HIV infection. Further study is needed to define the risk and pathophysiology of HIV in persons with SCD.

Published
2020

6. Biopsychosocial Factors Associated With Pain and Pain-Related Outcomes in Adults and Children With Sickle Cell Disease: A Multivariable Analysis of the GRNDaD Multicenter Registry

Author

Kenney, Martha O., primary, Wilson, Samuel, additional, Shah, Nirmish, additional, Bortsov, Andrey, additional, Smith, Wally R., additional, Little, Jane, additional, Lanzkron, Sophie, additional, Kanter, Julie, additional, Padrino, Susan, additional, Owusu-Ansah, Amma, additional, Cohen, Alice, additional, Desai, Payal, additional, Manwani, Deepa, additional, Rehman, Sana Saif Ur, additional, Hagar, Ward, additional, and Keefe, Francis, additional

Published
2023
Full Text
View/download PDF

9. Characterising the prevalence of overweight and obese status among adults with sickle cell disease.

Author

Ibemere, Stephanie O., Oyedeji, Charity I., Preiss, Liliana, Van Althuis, Laura E., Hankins, Jane S., Azul, Melissa, Burns, Ebony N., Glassberg, Jeffrey, Hagar, Ward, Hussain, Faiz, King, Allison, Melvin, Cathy, Myers, John, Snyder, Angela, Shah, Nirmish, and Tanabe, Paula

Subjects
SICKLE cell anemia, OBESITY, BODY mass index, ELECTRONIC health records, THALASSEMIA
Abstract

Summary: Individuals with sickle cell disease (SCD) have historically been considered underweight. Despite increasing body mass index (BMI) in the general population, the prevalence of overweight and obese status remains unclear in the adult SCD population. Our primary aim was to determine the prevalence of overweight and obese status and to identify associations between BMI, demographic, and clinical characteristics. We conducted an analysis of abstracted electronic health record data and patient‐reported outcomes from the Sickle Cell Disease Implementation Consortium registry; individuals aged 20–45 years were included. The median (interquartile range) BMI for the 1664 adults in this analysis was 23.9 (21.1–28) kg/m2. In this cohort, 42.9% had a BMI of >25 kg/m2 (Centers for Disease Control and Prevention definition of overweight/obese). In multivariable analysis, higher odds of being overweight or obese were associated with female gender, older age, college education, private insurance, and hypertension diagnosis. Higher odds of a BMI of >25 kg/m2 were observed in individuals with HbSC or HbSβ+ thalassaemia regardless of hydroxycarbamide (hydroxyurea) exposure (odds ratio [OR] 3.4, p < 0.0001) and HbSS or HbSβ0 thalassaemia exposed to hydroxycarbamide (OR 1.6, p = 0.0003) compared to those with HbSS or HbSβ0 thalassaemia with no hydroxycarbamide exposure. These data highlight the importance of early identification, prevention, and intervention for increasing BMI to reduce obesity‐related complications that may impact SCD‐related complications. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease

Author

Abrams, Donald I., Couey, Paul, Dixit, Niharika, Sagi, Varun, Hagar, Ward, Vichinsky, Elliott, Kelly, Mary Ellen, Connett, John E., and Gupta, Kalpna

Subjects
Adult, Male, Analgesics, Cross-Over Studies, Research, Pilot Projects, Hematology, Anemia, Sickle Cell, Medical Marijuana, Middle Aged, California, Online Only, Administration, Inhalation, Humans, Pain Management, Female, Original Investigation, Pain Measurement
Abstract

Key Points Question Is inhaled cannabis with an approximately 1:1 ratio of Δ-9-tetrahydrocannabinol to cannabidiol a safe and effective adjunct to opioids in adults with sickle cell disease–related pain? Findings This randomized clinical trial including 23 participants found that inhaled cannabis was safe. Inhaled cannabis was more effective than inhaled placebo in interference in mood, but there was no statistically significant difference in pain rating between cannabis and placebo. Meaning These findings suggest that cannabis should be investigated further in larger and longer clinical trials in adults with sickle cell disease with chronic pain as an adjunct or alternative to opioids., This randomized clinical trial examines the safety and efficacy of cannabis for pain in adults with sickle cell disease., Importance Sickle cell disease (SCD) is characterized by chronic pain and episodic acute pain caused by vasoocclusive crises, often requiring high doses of opioids for prolonged periods. In humanized mouse models of SCD, a synthetic cannabinoid has been found to attenuate both chronic and acute hyperalgesia. The effect of cannabis on chronic pain in adults with SCD is unknown. Objective To determine whether inhaled cannabis is more effective than inhaled placebo in relieving chronic pain in adults with SCD. Design, Setting, and Participants This pilot randomized clinical trial included participants with SCD with chronic pain admitted to a single inpatient clinical research center for 2 separate 5-day stays from August 2014 to April 2017. Participants inhaled either vaporized cannabis (4.4% Δ-9-tetrahydrocannabinol to 4.9% cannabidiol) 3 times daily or vaporized placebo cannabis. Pain and pain interference ratings using the Brief Pain Inventory were assessed throughout each 5-day period. Participants with SCD and chronic pain on stable analgesics were eligible to enroll. A total of 90 participants were assessed for eligibility; 56 participants were deemed ineligible, and 34 participants were enrolled. Of these, 7 participants dropped out before randomization. Of 27 randomized participants, 23 completed both treatment arms of the crossover study and were included in the final per protocol analysis. Data analysis was completed in June 2019, with the sensitivity analysis conducted in April 2020. Interventions Inhalation of vaporized cannabis plant (4.4% Δ-9-tetrahydrocannbinol to 4.9% cannabidiol) or placebo cannabis plant using a vaporizer 3 times daily for 5 days. Main Outcomes and Measures Daily pain assessed with visual analog scale and Brief Pain Inventory. Results A total of 23 participants (mean [SD] age, 37.6 [11.4] years; 13 [56%] women) completed the trial. The mean (SD) difference in pain rating assessment between the cannabis and placebo groups was −5.3 (8.1) for day 1, −10.9 (7.0) for day 2, −16.5 (9.2) for day 3, −8.9 (6.7) for day 4, and −8.2 (8.1) for day 5; however, none of these differences were statistically significant. There was no statistically significant mean (SD) difference in pain interference ratings between cannabis and placebo between days 1 and 5 for interference in general activities (day 1: 0.27 [0.35]; day 5: −1.0 [0.5]), walking (day 1: 0.14 [0.73]; day 5: −0.87 [0.63]), sleep (day 1: 0.59 [0.74]; day 5: −1.3 [0.8]), or enjoyment (day 1: 0.23 [0.69]; day 5: −0.91 [0.48]), but there was a statistically significant mean (SD) difference in decrease in interference with mood (day 1: 0.96 [0.59]; day 5: −1.4 [0.6]; P = .02). No differences in treatment-related adverse effects were observed. Use of concomitant opioids was similar during both treatment periods. Conclusions and Relevance This randomized clinical trial found that, compared with vaporized placebo, vaporized cannabis did not statistically significantly reduce pain and associated symptoms, except interference in mood, in patients with SCD with chronic pain. Trial Registration ClinicalTrials.gov Identifier: NCT01771731

Published
2020

25. Impact of an individualized pain plan to treat sickle cell disease vaso-occlusive episodes in the emergency department

Author

Siewny, Lauren, King, Allison, Melvin, Cathy L., Carpenter, Christopher R., Hankins, Jane S., Colla, Joseph S., Preiss, Liliana, Luo, Lingzi, Cox, Lisa, Treadwell, Marsha, Davila, Natalia, Masese, Rita V., McCuskee, Sarah, Gollan, S. Siera, Tanabe, Paula, Hodges, Jason, Carroll, Yvonne, Smeltzer, Matthew, Nwosu, Chinonyelum, Gurney, James, Potter, Jerlym, Badawy, Sherif, Estepp, Jeremie, Treadwell, Marsha, Vichinsky, Elliott, Wun, Ted, Potter, Michael, Hessler, Danielle, Hagar, Ward, Marsh, Anne, Neumayr, Lynne, Melvin, Cathy, Kanter, Julie, Phillips, Shannon, Adams, Robert, Mueller, Martina, Davila, Caroline, Nirmish Shah, Sarah Bourne., Tanabe, Paula, Bosworth, Hayden, Jackson, George, Richesson, Rachel, Prvu-Bettger, Janet, Masese, Rita, DeMartino, Terri, Kutlar, Abdullah, Gibson, Robert, Snyder, Angela, Fernandez, Maria, Lyon, Matthew, Lottenberg, Richard, Lawrence, Raymona, Gollan, Sierra, Bowman, Latanya, Richardson, Lynne, Glassberg, Jeffrey, Simon, Jena, Loo, George T., Clesca, Cindy, Linton, Elizabeth, Ryan, Gery, Gordeuk, Victor, Hirschtick, Jana, Hsu, Lewis, Krishnan, Jerry, Wandersman, Abe, Colla, Joe, Erwin, Kim, Lamont, Andrea, Norell, Sarah, Saving, Kay, Nocek, Judith, King, Allison, Baumann, Ana, Calhoun, CeCe, Luo, Lingzi, James, Aimee, Abel, Regina, Varughese, Taniya, Kroner, Barbara, Rojas-Smith, Lucia, Hendershot, Tabitha, DiMartino, Lisa, Jacobs, Sara, Battestilli, Whitney, Brambilla, Don, Cox, Lisa, Preiss, Liliana, Pugh, Norma, Telfair, Joseph, Hassell, Kathryn, Thompson, Alexis, Tompkins, William, Smith, Sharon, Luksenberg, Harvey, Peters-Lawrence, Marlene, Boyce, Cheryl, Barfield, Whitney, and Werner, Ellen

Abstract

•Both patients with sickle cell and ED providers strongly endorse IPPs.•Collaboration among specialties, including informatics and patients, is needed to successfully implement IPPs.

Published
2024
Full Text
View/download PDF

29. Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management

Author

Ballas, Samir K., Kesen, Muge R., Goldberg, Morton F., Lutty, Gerard A., Dampier, Carlton, Osunkwo, Ifeyinwa, Wang, Winfred C., Hoppe, Carolyn, Hagar, Ward, Darbari, Deepika S., and Malik, Punam

Subjects
Article Subject
Abstract

The sickle hemoglobin is an abnormal hemoglobin due to point mutation (GAG → GTG) in exon 1 of the β globin gene resulting in the substitution of glutamic acid by valine at position 6 of the β globin polypeptide chain. Although the molecular lesion is a single-point mutation, the sickle gene is pleiotropic in nature causing multiple phenotypic expressions that constitute the various complications of sickle cell disease in general and sickle cell anemia in particular. The disease itself is chronic in nature but many of its complications are acute such as the recurrent acute painful crises (its hallmark), acute chest syndrome, and priapism. These complications vary considerably among patients, in the same patient with time, among countries and with age and sex. To date, there is no well-established consensus among providers on the management of the complications of sickle cell disease due in part to lack of evidence and in part to differences in the experience of providers. It is the aim of this paper to review available current approaches to manage the major complications of sickle cell disease. We hope that this will establish another preliminary forum among providers that may eventually lead the way to better outcomes.

Published
2012
Full Text
View/download PDF

31. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease

Author

Kutlar, Abdullah, primary, Ataga, Kenneth I., additional, McMahon, Lillian, additional, Howard, Joanna, additional, Galacteros, Frederic, additional, Hagar, Ward, additional, Vichinsky, Elliott, additional, Cheung, Anthony T.W., additional, Matsui, Neil, additional, and Embury, Stephen H., additional

Published
2012
Full Text
View/download PDF

32. The third described case of transfusion‐transmitted Babesia duncani

Author

Bloch, Evan M., primary, Herwaldt, Barbara L., additional, Leiby, David A., additional, Shaieb, Annette, additional, Herron, Ross M., additional, Chervenak, Michael, additional, Reed, William, additional, Hunter, Robert, additional, Ryals, Rosilyn, additional, Hagar, Ward, additional, Xayavong, Maniphet V., additional, Slemenda, Susan B., additional, Pieniazek, Norman J., additional, Wilkins, Patricia P., additional, and Kjemtrup, Anne M., additional

Published
2011
Full Text
View/download PDF

37. Hospitalization Rate and Regional Differences in Comprehensive Care in Transfused Patients with Sickle Cell Disease Compared to Thalassemia: A Report from the Multi-Center Study of Iron Overload.

Author

Fung, Ellen B., primary, Harmatz, Paul, primary, Milet, Meredith, primary, Ballas, Samir K., primary, DeCastro, Laura, primary, Hagar, Ward, primary, Hilliard, Lee, primary, Owen, William, primary, Smith-Whitley, Kim, primary, and Vichinsky, Elliott, primary

Published
2005
Full Text
View/download PDF

41. Arginine Therapy

Author

Morris, Claudia R., primary, Morris, Sidney M., additional, Hagar, Ward, additional, van Warmerdam, Jane, additional, Claster, Susan, additional, Kepka-Lenhart, Diane, additional, Machado, Lorenzo, additional, Kuypers, Frans A., additional, and Vichinsky, Elliott P., additional

Published
2003
Full Text
View/download PDF

44. Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression.

Author

Jenkins ZA, Hagar W, Bowlus CL, Johansson HE, Harmatz P, Vichinsky EP, and Theil EC

Subjects
Gene Expression Regulation, Hepcidins, Humans, Iron Overload etiology, Iron Regulatory Protein 1 genetics, Iron Regulatory Protein 2 genetics, Oxidative Stress, RNA, Messenger analysis, Transfusion Reaction, Anemia, Sickle Cell complications, Antimicrobial Cationic Peptides genetics, Ferritins genetics, Homeostasis genetics, Iron metabolism, Iron Overload metabolism, Iron-Regulatory Proteins genetics, beta-Thalassemia complications
Abstract

Hypertransfusional (>8 transfusions/year) iron in liver biopsies collected immediately after transfusions in beta-thalassemia and sickle cell disease correlated with increased expression (RNA) for iron regulatory proteins 1 and 2 (3-, 9- to 11-fold) and hepcidin RNA: (5- to 8-fold) (each p <.01), while ferritin H and L RNA remained constant. A different H:L ferritin ratio in RNA (0.03) and protein (0.2-0.6) indicated disease-specific trends and suggests novel post-transcriptional effects. Increased iron regulatory proteins could stabilize the transferrin receptor mRNA and, thereby, iron uptake. Increased hepcidin, after correction of anemia by transfusion, likely reflects excess liver iron. Finally, the absence of a detectable change in ferritin mRNA indicates insufficient oxidative stress to significantly activate MARE/ARE promoters.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results